This is a personal research note, not medical advice. Racetams are prescription medicines in some countries and unapproved drugs in others. I do not recommend taking any of them or suggest doses; where doses appear, they are the amounts used in published studies, quoted for context. The images are AI-generated illustrations, not chemical diagrams or products.
01 / THE FAMILY
One ring, many variations.
The racetams are synthetic compounds that share a 2-oxopyrrolidine ring. Most also keep piracetam’s acetamide side chain; the rest is chemistry hung off the same frame.
The story starts at UCB in Belgium in 1964. A team led by Corneliu Giurgea was looking for a sleep-inducing GABA analogue. Piracetam did not sedate anyone. In animals it instead seemed to protect learning and memory against insults such as low oxygen. In 1972 Giurgea coined a word for that profile: nootropic, from the Greek for “mind” and “turning”.
Over the next two decades, other laboratories built their own analogues: Roche, Parke-Davis, Daiichi, Mitsubishi Tanabe, an Italian firm, and a Moscow institute that supported the Soviet space programme. UCB’s later anticonvulsants, levetiracetam and brivaracetam, share the same scaffold but act on a known target. For the “cognitive” racetams, the mechanism is still not settled.
02 / THE EVIDENCE MAP
The most talked-about racetams have the least human data.
The racetams that get talked about most online are often the ones with the least human data. This map puts each compound where the published studies put it.
03 / SEVEN DOSSIERS
Compound by compound.
01 / PIRACETAM
Piracetam, the parent.
- What it is
- The original racetam: 2-oxo-1-pyrrolidine acetamide, a cyclic relative of GABA. It is absorbed almost completely and leaves the body unchanged in urine.
- How it is thought to work
- The UK prescribing information says plainly that its mode of action is “as yet unknown”. Candidate explanations include restoring cell-membrane fluidity and effects on blood flow. Its effects on platelets and fibrinogen are documented; a weak AMPA effect is proposed.
- What the human studies show
- Its strongest evidence is in cortical myoclonus, a movement disorder. In a 21-patient crossover trial, 10 patients needed rescue treatment on placebo and none did on piracetam. For cognition the picture is weak: the Cochrane review found a better global impression of change but no benefit on specific cognitive tests, and does not support its use in dementia. A 2024 meta-analysis also found no proven memory benefit. Studies in healthy adults are small and date from the 1970s.
- What it is used for
- Prescribed in some countries for cortical myoclonus. It was historically used for cognitive decline, vertigo and dyslexia, and is sold online as a memory and focus aid.
- Doses in studies (not advice)
- 2.4–4.8 g a day in cognition studies; 7.2 g a day upwards in myoclonus, per the UK label. Cognitive effects, where seen, took at least two weeks to appear.
- Cautions and status
- It reduces platelet aggregation, so it needs care with anticoagulants, antiplatelets (including low-dose aspirin), bleeding risk or surgery. It is contraindicated in severe kidney impairment. UK: prescription-only, for myoclonus only. US: not approved; the FDA says it is not a dietary ingredient.
SOURCES / Cochrane review ↗ · UK SmPC ↗ · Myoclonus trial ↗ · 2024 meta-analysis ↗
02 / ANIRACETAM
Aniracetam, the clearest mechanism.
- What it is
- N-anisoyl-2-pyrrolidinone. It keeps the ring but, unusually, has no acetamide side chain, so “piracetam plus a group” is the wrong description. It dissolves poorly in water.
- How it is thought to work
- It has the best-established mechanism of the cognitive racetams: AMPA receptor positive allosteric modulation. It slows how quickly glutamate’s fast receptors switch off, as shown in hippocampal tissue. The catch is that it is weak at the receptor and broken down within minutes. Its metabolites may do part of the work, and it is unclear whether the AMPA effect occurs at human doses.
- What the human studies show
- Older dementia trials reported benefit at 1.5 g a day over 4–6 months. In a scopolamine challenge (a drug-induced memory deficit), it blunted the deficit in healthy volunteers. A 44-person crossover trial in solvent-induced brain injury was negative. There is no meta-analysis and no modern trial in healthy adults.
- What it is used for
- Historically prescribed in some countries for age-related cognitive disorders. It is marketed online for focus, mood and anxiety; the anxiety claims rest mostly on rodent data.
- Doses in studies (not advice)
- 1–1.5 g a day in clinical trials; 200–400 mg single doses in pharmacokinetic work.
- Cautions and status
- Reported side effects in trials include headache, nervousness and insomnia, but systematic safety data are thin. Its metabolites build up in kidney impairment. US: named an unapproved new drug in a 2019 FDA warning letter. Its Italian approval appears historical: Italy’s medicines database lists no current product.
SOURCES / Clinical review ↗ · Pharmacokinetics ↗ · Supplement analysis ↗
03 / OXIRACETAM
Oxiracetam, the split verdict.
- What it is
- 4-hydroxy-piracetam: piracetam with one added hydroxyl group, which makes it the most hydrophilic racetam here. One mirror-image form, S- or “L-oxiracetam”, is now in development in China.
- How it is thought to work
- Uncertain. Proposed mechanisms include weak AMPA modulation, more acetylcholine release, and protein kinase C activation, mostly from animal studies.
- What the human studies show
- Small Italian dementia trials in the 1980s and 1990s were mixed. Two large modern trials disagree. In Korea, a 500-patient trial to prevent cognitive decline after stroke found no benefit (2026). In China, a 590-patient phase 3 trial in traumatic brain injury found a moderate cognitive benefit, mainly for L-oxiracetam (2025).
- What it is used for
- Used clinically in parts of Asia for cognitive problems after stroke or brain injury. Online it is sold as a “logic” racetam, a claim no study supports.
- Doses in studies (not advice)
- 800 mg twice a day in dementia and stroke trials; 4 g a day of L-oxiracetam and 6 g a day of the racemic mixture in the brain-injury trial.
- Cautions and status
- Generally well tolerated in trials. It is cleared by the kidneys: its half-life rose from 3–6 hours to as much as 68 hours in kidney impairment. US: unapproved new drug. Its Italian approval appears to have lapsed.
SOURCES / Post-stroke trial ↗ · Brain-injury trial ↗ · Pharmacokinetics ↗
04 / PRAMIRACETAM
Pramiracetam, little data.
- What it is
- Piracetam’s acetamide with a bulky diisopropylaminoethyl group attached (research code CI-879). It is a moderately fat-loving base, usually made as a water-soluble sulfate salt.
- How it is thought to work
- Uncertain. Rodent work suggests it increases high-affinity choline uptake in the hippocampus, the supply step for making acetylcholine. It barely binds the major receptors, and its memory effect in animals follows an inverted U: too much works less well.
- What the human studies show
- A small placebo-controlled study in young men with brain injury reported better memory, especially delayed recall. A small Alzheimer’s dose-finding trial concluded that doses up to 4 g were “unlikely to confer symptomatic benefit”. In healthy volunteers it partly blunted scopolamine-induced amnesia. There is no meta-analysis.
- What it is used for
- Once prescribed in Italy for memory and attention problems in older adults. It is sold online for memory and focus.
- Doses in studies (not advice)
- 400 mg three times a day in the brain-injury study; 600 mg twice a day in the scopolamine model; up to 4 g a day in the Alzheimer’s dose-finding trial.
- Cautions and status
- Well tolerated in small studies, but there are almost no systematic safety or interaction data. US: unapproved new drug. Italy’s database lists no current product.
SOURCES / Brain-injury study ↗ · Alzheimer’s trial ↗ · Pharmacokinetics ↗
05 / PHENYLPIRACETAM
Phenylpiracetam, the stimulant.
- What it is
- 4-phenyl-piracetam, also called fonturacetam or carphedon and sold in Russia as Phenotropil. Often called fat-soluble, its measured lipophilicity is actually close to neutral.
- How it is thought to work
- Unlike its siblings, it has a recognisable stimulant mechanism: both of its mirror-image forms inhibit the dopamine transporter. It acts as a psychostimulant in animals. Human mechanism data are lacking.
- What the human studies show
- Almost all of the evidence is Russian-language and of mixed quality. It includes a 90-patient add-on trial in epilepsy, a 400-patient stroke-rehabilitation study that appears non-randomised, and a large observational programme in fatigue. There are no Western randomised trials and none in healthy adults.
- What it is used for
- Prescribed in Russia for asthenia (fatigue), circulation problems in the brain, and memory and attention complaints. Online it is marketed for energy, cold tolerance and physical performance.
- Doses in studies (not advice)
- 100–200 mg a day in the epilepsy trial; 400 mg a day in the stroke study.
- Cautions and status
- Reported effects include sleep disturbance, agitation and irritability. Its dopaminergic profile raises misuse and stimulant-stacking concerns. Sport: named on the WADA 2026 Prohibited List as a non-specified stimulant (S6.A), banned in competition. Russia: prescription-only. US: unapproved new drug.
SOURCES / WADA 2026 list ↗ · Dopamine transporter study ↗ · Epilepsy trial ↗
06 / COLURACETAM
Coluracetam, mostly animal data.
- What it is
- The racetam acetamide fused to a bulky tetrahydrofuroquinoline ring system (research codes MKC-231 and BCI-540). It is the most fat-loving of the seven.
- How it is thought to work
- It enhances high-affinity choline uptake, apparently by putting more choline transporters at the nerve ending. In rats it restored memory after the cholinergic system was chemically damaged, but did nothing in normal rats. All mechanism data come from animal or cell studies.
- What the human studies show
- Effectively nothing published. A 115-patient phase 2 trial in depression with anxiety finished in 2009 with no results posted. The “positive signal” people quote comes from a 2010 company press release that was never peer-reviewed.
- What it is used for
- Marketed online for memory, mood and “vision enhancement”. The vision claim extrapolates from rat retina-injury studies.
- Doses in studies (not advice)
- 80 mg once or three times a day for six weeks in the unpublished depression trial.
- Cautions and status
- There are no published human safety data and the interaction profile is unknown. It has never been approved anywhere.
SOURCES / NCT00621270 ↗ · Transporter study ↗ · Rat lesion model ↗
07 / NEFIRACETAM
Nefiracetam, the honest negative.
- What it is
- The piracetam core with a 2,6-dimethylphenyl group on the amide (research code DM-9384). It is fat-loving and broken down in the liver into active metabolites.
- How it is thought to work
- It has a rich mechanism in the lab: it potentiates calcium channels, nicotinic receptors and NMDA receptors through kinase pathways, and has GABA effects. Whether any of this matters in people is unknown.
- What the human studies show
- It has the best-designed modern trials of the non-piracetam racetams, and they were largely negative. In a 159-patient trial in post-stroke depression it was not effective; placebo response exceeded 70%. A signal for post-stroke apathy at 900 mg came from a subgroup, and a later confirmatory trial, though underpowered, found no difference from placebo.
- What it is used for
- Never approved. It is sold online for memory, mood and motivation, on the strength of animal work and the early apathy subgroup.
- Doses in studies (not advice)
- 600 and 900 mg a day in the post-stroke trials.
- Cautions and status
- Tolerated in those trials, but long-term human safety is unknown. Development for Alzheimer’s disease was discontinued, and it is not approved anywhere.
SOURCES / Depression trial ↗ · Apathy trial ↗ · Alzforum status ↗
04 / SIDE BY SIDE
The seven in one ledger.
| Compound | Proposed mechanism | Best human evidence | Half-life | Status today |
|---|---|---|---|---|
| Piracetam | Unknown; membrane and blood-flow effects | Positive in cortical myoclonus; no specific cognitive benefit in reviews | ≈ 5 h | Prescription in UK (myoclonus) and Italy; unapproved in US |
| Aniracetam | AMPA positive allosteric modulator | Small, old dementia trials; scopolamine model | ≈ 0.5 h | No current approval found; unapproved in US |
| Oxiracetam | Uncertain; cholinergic and AMPA proposals | Two large trials: negative after stroke, positive after brain injury | 3–6 h | Clinical use in parts of Asia; Italian approval lapsed |
| Pramiracetam | Choline uptake (rodent data) | A few very small studies, one negative | 4.5–6.5 h | No current approval found; unapproved in US |
| Phenylpiracetam | Dopamine transporter inhibitor | Russian trials and observational data | ≈ 3–5 h* | Prescription in Russia; WADA-prohibited in competition |
| Coluracetam | Choline uptake enhancer (animal data) | One phase 2 trial, results never posted | Unknown | Never approved |
| Nefiracetam | Calcium, nicotinic and NMDA effects (lab data) | Several trials, main endpoints negative | 3–5 h | Never approved; development discontinued |
*PHENYLPIRACETAM HALF-LIFE FROM A SECONDARY SOURCE; THE RUSSIAN LABEL COULD NOT BE RETRIEVED.
05 / OFTEN MENTIONED
Relatives and look-alikes.
Noopept
Often filed with the racetams, but not one. It is a proline-containing dipeptide (omberacetam) with no 2-oxopyrrolidine ring, developed in Russia as a “peptide analogue” of piracetam. The relationship is historical and pharmacological, not structural.
Levetiracetam
A widely used anti-seizure medicine from UCB, built on the same scaffold. Unlike the cognitive racetams it has a defined target, synaptic vesicle protein 2A (SV2A). That shows the ring can carry a clear mechanism; levetiracetam is not a cognitive enhancer.
Brivaracetam
A newer UCB anti-seizure medicine with 15–30 times higher SV2A affinity than levetiracetam. It was approved by the FDA in 2016 for focal seizures and is a controlled prescription drug in the US.
06 / LEGAL STATUS
Legal status is a patchwork.
In the United States, the FDA treats these compounds as unapproved new drugs. A 2019 warning letter named piracetam, aniracetam, oxiracetam, phenylpiracetam and pramiracetam, and an earlier FDA position says piracetam is not a dietary ingredient. Independent testing has found racetams in “supplements” at unpredictable doses, sometimes undeclared.
In the UK, piracetam is prescription-only and licensed only for cortical myoclonus. In Italy it is a prescription medicine, while the other racetams once sold there no longer appear in the national database. Phenylpiracetam is prescription-only in Russia and banned in competitive sport. I could not find an official UAE registration source for any of the seven, so I am not stating a UAE status.
One racetam has a proven use, piracetam for a rare movement disorder. One has a well-understood mechanism, aniracetam at AMPA receptors, but that mechanism has not been shown to work at human doses. Large modern trials of oxiracetam and nefiracetam were mostly negative. None of the seven has good evidence for improving thinking in healthy adults. Anyone considering a prescription medicine should talk to a doctor.